Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study.

Schultheis, Beate; Strumberg, Dirk; Kuhlmann, Jan; Wolf, Martin; Link, Karin; Seufferlein, Thomas; Kaufmann, Joerg; Feist, Mathilde; Gebhardt, Frank; Khan, Mike; Stintzing, Sebastian; Pelzer, Uwe

Schultheis, Beate; Strumberg, Dirk; Kuhlmann, Jan; Wolf, Martin; Link, Karin; Seufferlein, Thomas; Kaufmann, Joerg; Feist, Mathilde; Gebhardt, Frank; Khan, Mike; Stintzing, Sebastian; Pelzer, Uwe.

Afiliação

Schultheis B; Department of Hematology and Oncology, Marien Hospital Herne, University of Bochum, 44627 Herne, Germany.
Strumberg D; Department of Hematology and Oncology, Marien Hospital Herne, University of Bochum, 44627 Herne, Germany.
Kuhlmann J; Department of Medicine II, University Hospital Freiburg, 79106 Freiburg, Germany.
Wolf M; Department of Medicine, Hospital Kassel, 34125 Kassel, Germany.
Link K; Department of Medicine V, Hospital Nuernberg Nord, 90419 Nuernberg, Germany.
Seufferlein T; Department of Medicine I, Universitätsklinikum Ulm, 89081 Ulm, Germany.
Kaufmann J; Silence Therapeutics GmbH, 13125 Berlin, Germany.
Feist M; Department of Surgery, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Gebhardt F; Medical faculty, Humboldt-Universität zu Berlin, 10099 Berlin, Germany.
Khan M; Berlin Institute of Health, 10178 Berlin, Germany.
Stintzing S; Silence Therapeutics GmbH, 13125 Berlin, Germany.
Pelzer U; Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK.